Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

QMF149

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Rationale Long-Acting Beta2-Agonist/Inhaled Corticosteroids (LABA/ICS) Fixed-Dose Combinations (FDCs) have been found to be safe… Expand
2018
2018
Background and purpose Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2016
2016
PURPOSE QMF149 is a fixed-dose combination of the long-acting β2 agonist, indacaterol and the corticosteroid, mometasone furoate… Expand
2016
2016
This single‐dose, 4‐period crossover study evaluated the pharmacokinetics (PK) of the β2‐agonist indacaterol maleate and the… Expand
2015
2015
Objective To investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist… Expand
2015
2015
OBJECTIVES This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149, a novel… Expand
2014
2014
Introduction QMF149 is an investigational inhaled fixed-dose combination of indacaterol acetate and mometasone furoate via the… Expand
2012
2012
QMF is an investigational once-daily (QD), fixed-dose combination of indacaterol (IND) and mometasone furoate (MF). This study… Expand
2012
2012
QMF is an investigational once-daily (QD) fixed-dose combination of indacaterol (IND) and mometasone furoate (MF). The efficacy… Expand